Opna Bio develops
drugs targeting the
Hallmarks of Cancer

OPN-2853

BET
Inhibitor

Nonmutational epigenetic
reprogramming

OPN-FMRP

FMRP
Inhibitor

Avoiding immune
destruction

OPN-6602

Dual Inhibitor
of EP300 and CBP

Nonmutational epigenetic
reprogramming

OUR PIPELINE

Opna Bio is targeting master regulators to advance the treatment of cancer. These include OPN-6602, a best-in-class EP300/CBP inhibitor, currently in clinical development for treatment of multiple myeloma patients.

EXPLORE
Hanahan et al, November 2022

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Upregulation of the neuronal fragile-X multifunctional RNA-binding protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity

Read More

LATEST NEWS

11 /2024

Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma

Opna Announces ASH abstracts 2024

08 /2024

Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor

Appoints Axel Bolte, MBA, MSc to Board Director and Stephanie Oestreich, PhD, MPA to Board Observer

Read More News